Scienture Holdings, Inc. (Nasdaq: SCNX) has entered into a securities purchase agreement with institutional investors for the purchase of 3,225,000 shares of common stock at $1.20 per share.
The gross proceeds from the offering are expected to be approximately $3.9 million before deducting fees and expenses.
The offering is set to close on August 15, 2025, subject to customary closing conditions.
Offering Details
3,225,000 shares of common stock to be purchased at $1.20 per share.
Gross Proceeds
Expected to reach approximately $3.9 million before deductions.
Closing Date
The offering is scheduled to close on August 15, 2025.
Placement Agent
Maxim Group LLC is the sole placement agent for the offering.
Registration Statement
Offering made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-289198) filed on August 1, 2025.
- The offering provides Scienture Holdings, Inc. with additional capital to support its pharmaceutical operations and growth.
- Institutional investor participation indicates confidence in Scienture's strategic direction and future prospects.
The registered direct offering of common stock by Scienture Holdings, Inc. is a strategic move to raise capital for further development and expansion within the pharmaceutical industry.